Dr. Kwong highlights work on protease sensors for NASH at Keystone Symposium


The global prevalence of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has risen precipitously over the past two decades in parallel with the worldwide obesity epidemic, and these diseases are associated with progressive fibrosis and an increased risk of liver cancer. The field lacks an integrated understanding of risk prediction, pathogenesis and validated biomarkers to predict or track disease progression without reliance on liver biopsies. Dr. Kwong presented work from our lab and Glympse Bio harnessing synthetic biomarkers as protease activity sensors for noninvasive monitoring of NASH.